The Technical Analyst
Minerva Neurosciences Inc [NERV]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Minerva Neurosciences Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
-1.59% $2.48
America/New_York / 25 apr 2024 @ 11:48
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 17.34 mill |
| EPS: | -4.61 |
| P/E: | -0.540 |
| Earnings Date: | May 13, 2024 |
| SharesOutstanding: | 6.99 mill |
| Avg Daily Volume: | 0.121 mill |
| RATING 2024-04-25 |
|---|
| B |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Strong Buy | |
| Return On Asset: | Sell | |
| DE: | Strong Sell | |
| P/E: | Neutral | |
| Price To Book: | Strong Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | n/a | n/a | ||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.540 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.09x |
| Company: PE -0.540 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 2.15 - 2.81 ( +/- 13.19%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2023-10-04 | Luthringer Remy | Buy | 100 450 | Employee Stock Option (right to buy) |
| 2023-10-04 | Race Geoff | Buy | 87 050 | Employee Stock Option (right to buy) |
| 2023-10-04 | Ahlholm Frederick W | Buy | 42 850 | Employee Stock Option (right to buy) |
| 2023-09-27 | Hasler Hans Peter | Buy | 12 500 | Stock Option (right to buy) |
| 2023-09-27 | Van Heek G Jan | Buy | 12 500 | Stock Option (right to buy) |
| INSIDER POWER |
|---|
| 34.35 |
| Last 97 transactions |
| Buy: 4 702 257 | Sell: 460 450 |
Forecast:
13:27 - $2.50
Live Trading Signals (every 1 min)
Forecast
1: 11:57 - $2.50
Forecast 2: 12:47 - $2.50
Forecast 3: 13:27 - $2.50
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $2.48 (-1.59% ) |
| Volume | 0.0042 mill |
| Avg. Vol. | 0.121 mill |
| % of Avg. Vol | 3.47 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For NERV
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
NERV
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone for the treatment of schizophrenia; and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. Minerva Neurosciences, Inc. has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. The company was formerly known as Cyrenaic Pharmaceuticals, Inc. and changed its name to Minerva Neurosciences, Inc. in 2013. Minerva Neurosciences, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.
Latest Press Releases
2024-02-22 07:00:00 - Press Release
Minerva Neurosciences Reports Fourth Quarter And Fiscal Year 2023 financial Results And Business Updates
Burlington, mass., feb. 22, 2024 (globe newswire) -- minerva neurosciences, inc. (nasdaq: nerv), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today reported business updates and financial results for the fourth quarter and year ended december 31, 2023.
2023-11-07 07:30:00 - Press Release
Minerva Neurosciences Reports 2023 Third Quarter financial Results And Business Updates
Burlington, mass., nov. 07, 2023 (globe newswire) -- minerva neurosciences, inc. (nasdaq: nerv), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today reported business updates and financial results for the third quarter ended september 30, 2023.
2023-08-01 07:30:00 - Press Release
Minerva Neurosciences Reports 2023 Second Quarter Financial Results And Business Updates
Burlington, mass., aug. 01, 2023 (globe newswire) -- minerva neurosciences, inc. (nasdaq: nerv), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today reported business updates and financial results for the second quarter ended june 30, 2023.
2023-06-28 08:30:00 - Press Release
Minerva Neurosciences Announces $20 Million In Private Placement Priced At A Premium To Market
Burlington, mass., june 28, 2023 (globe newswire) -- minerva neurosciences, inc. (nasdaq: nerv), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today announced that it has agreed to sell an aggregate of 1,425,000 shares of its common stock at a purchase price of $10 per share and pre-funded warrants to purchase an aggregate of 575,575 shares of its common stock at a purchase price of $9.99 per pre-funded warrant, to boehringer ingelheim, a global biopharmaceutical company with a growing mental health pipeline that includes schizophrenia, and federated hermes kaufmann funds in a private investment in public equity (the “pipe”) financing...
2023-05-15 07:30:00 - Press Release
Minerva Neurosciences Reports 2023 First Quarter financial Results And Business Updates
Burlington, mass., may 15, 2023 (globe newswire) -- minerva neurosciences, inc. (nasdaq: nerv), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today reported business updates and financial results for the first quarter ended march 31, 2023.
Latest News
2024-02-27 08:14:13 - Reuters
US FDA declines to approve Minerva Neurosciences' schizophrenia drug
Minerva Neurosciences said on Tuesday the U.S. Food and Drug Administration has declined to approve its experimental drug for the treatment of negative symptoms in patients with schizophrenia.
2023-08-23 04:05:12 - Seeking Alpha
Minerva Neurosciences: There's Probably Time For One More Rally
Minerva Neurosciences has raised $20M through a private placement at a premium to market prices. Boehringer Ingelheim participated in the private placement. Boehringer is itself developing a drug for schizophrenia, albeit for cognitive impairments associated with schizophrenia. NERV has six months until the PDUFA goal date for its roluperidone application but used only $4M in cash in operating activities in Q2, so cash isn't currently a concern.
2023-06-09 10:57:14 - Zacks Investment Research
Here's Why Minerva Neurosciences (NERV) Is a Great 'Buy the Bottom' Stock Now
Minerva Neurosciences (NERV) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
2023-06-05 14:11:04 - Zacks Investment Research
Nasdaq ETF's First Six-week Rally Since Jan 2020: Stock Winners
Nasdaq ETF marked first six-week rally since Jan 2020. These stocks gained more than 100% during this time frame.
2023-05-19 17:34:30 - Seeking Alpha
Minerva Neurosciences: Up About 250 Percent Since April With An FDA Catalyst Ahead
NERV has once again run on the submission of an NDA for roluperidone for the treatment of negative symptoms in schizophrenia. There will be no Refusal to File letter this time, with NERV using a dispute resolution process to its advantage.
2023-05-18 13:02:05 - Zacks Investment Research
What Makes Minerva Neurosciences (NERV) a New Buy Stock
Minerva Neurosciences (NERV) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
2023-05-08 08:30:00 - GlobeNewsWire
Minerva Neurosciences to Report First Quarter 2023 Financial Results and Business Updates on May 15, 2023
BURLINGTON, Mass., May 08, 2023 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that it will release first quarter 2023 financial results and business updates on Monday, May 15, 2023.
2023-03-08 11:31:09 - Seeking Alpha
Minerva Neurosciences, Inc. (NERV) Q4 2022 Earnings Call Transcript
Minerva Neurosciences, Inc. (NASDAQ:NERV ) Q4 2022 Earnings Conference Call March 8, 2023 8:30 AM ET Company Participants Geoff Race - President Remy Luthringer - CEO Fred Ahlholm - CFO Conference Call Participants Andrew Tsai - Jefferies Douglas Tsao - H.C. Wainwright Operator Good day, and thank you for standing by.
2023-03-01 08:30:00 - GlobeNewsWire
Minerva Neurosciences to Report Fiscal Year 2022 Financial Results and Business Updates on March 8, 2023
2022-12-29 12:02:16 - Zacks Investment Research
Minerva (NERV) Down; FDA Denies Review Schizophrenia Drug NDA
Minerva (NERV) confirmed that the FDA's refuse-to-file letter on its regulatory filing, seeking approval for roluperidone, to treat symptoms of schizophrenia remains in effect.